Form	Number of Respond- ents	Number of Responses/ Respond- ents	Average Burden/Re- sponse (in hours)
Non-response Study	50	1	2

Dated: July 29, 2002.

Nancy Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention.

[FR Doc. 02–19514 Filed 8–1–02; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 02175]

Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: Applied Research on
Antimicrobial Resistance: Validation
of National Committee for Clinical
Laboratory Standards Breakpoints for
Human Pathogens of Public Health
Importance

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Applied Research on Antimicrobial Resistance (AR): Validation of National Committee for Clinical Laboratory Standards (NCCLS) Breakpoints for Human Pathogens of Public Health Importance, PA 02175

Times And Date: 8:30 a.m.—9 a.m., August 22, 2002 (Open); 9:15 a.m.—12:00 p.m., August 22, 2002 (Closed).

Place: Atlanta Airport Hilton, 1031 Virginia Avenue, Atlanta, GA 30354.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters to be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to PA 02175.

Contact Person for More Information: Marsha A. Jones, Health Scientist, National Center for Infectious Diseases, CDC, 1600 Clifton Road, NE, MS C–12, Atlanta, Georgia 30333, 404–639–2603, e-mail: maj4@cdc.gov.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: July 29, 2002.

John Burckhardt,

Acting Director, Management Analysis and Services Office.

[FR Doc. 02–19511 Filed 8–1–02; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: Interventional
Epidemiologic Research Studies To
Reduce Mother-to-Child HIV-1
Transmission and Improve Infant
Survival in Resource-Limited
Countries of High HIV-1
Seroprevalence, Program
Announcement 02074

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting:

Name: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Interventional Epidemiologic Research Studies to Reduce Mother-to-Child HIV–1 Transmission and Improve Infant Survival in Resource-Limited Countries of High HIV–1 Seroprevalence, Program Announcement 02074.

Times and Dates: 9 a.m.—9:30 a.m., August, 28, 2002 (Open) 9:30 a.m.—4:30 p.m., August 28, 2002 (Closed).

Place: Double Tree Hotel, 3342 Peachtree Road, NE, Atlanta, GA.

Status: Portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c) (4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92–463.

Matters To Be Discussed: The meeting will include the review, discussion, and evaluation of applications received in response to PA# 02074.

Contact Person for More Information: Beth Wolfe, Prevention Support Office, National Center for HIV, STD, and TB Prevention, CDC, 1600 Clifton Road NE MS E-07, Atlanta, Georgia 30333, 404–639–8025.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: July 29, 2002.

John Burckhardt,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 02–19512 Filed 8–1–02; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Science and Program Review Subcommittee (SPRS) and the Advisory Committee for Injury Prevention and Control (ACIPC): Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following subcommittee and committee meetings:

Name: Science and Program Review Subcommittee to ACIPC.

Time and Dates: 6:30 p.m.–9 p.m., August 18, 2002. 9 a.m.–12 p.m., August 19, 2002.

Place: The Westin Atlanta Airport, 4736 Best Road, College Park, Georgia 30337. Status: Open: 6:30 p.m.-7 p.m., August 19

Status: Open: 6:30 p.m.–7 p.m., August 18, 2002. Closed: 7 p.m.–9 p.m., August 18, 2002, through 12 p.m., August 19, 2002.

Purpose: The Subcommittee provides advice on the needs, structure, progress and performance of the National Center for Injury Prevention and Control (NCIPC) programs. The Subcommittee provides second-level scientific and programmatic review for applications for research grants, cooperative agreements, and training grants related to injury control and violence prevention, and recommends approval of projects that merit further consideration for funding support. The Subcommittee also advises on priorities for research to be supported by contracts, grants, and cooperative agreements and provides concept review of program proposals and announcements.